New Inhibitory Effect of Latilactobacillus sakei UONUMA on the Cholesterol Biosynthesis Pathway in Human HepG2 Cells

Many pharmaceuticals and dietary foods have been reported to inhibit cholesterol biosynthesis, mainly by inhibiting the presqualene enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase rather than a postsqualene enzyme. In this study, we examined the inhibitory effects of Latilactobacillus sake...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2021/04/01, Vol.44(4), pp.485-493
Main Authors: Ohta-Shimizu, Miho, Fuwa, Fumiko, Tomitsuka, Eriko, Nishiwaki, Toshikazu, Aihara, Kotaro, Sato, Shinji, Nakagawa, Saori
Format: Article
Language:English
Subjects:
Biosynthesis
Cholesterol
desmosterol
Enzymes
Hepatoma
Hyperlipidemia
Latilactobacillus sakei UONUMA
mRNA
sterol-delta24-reductase
Sulfur
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many pharmaceuticals and dietary foods have been reported to inhibit cholesterol biosynthesis, mainly by inhibiting the presqualene enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase rather than a postsqualene enzyme. In this study, we examined the inhibitory effects of Latilactobacillus sakei UONUMA on cholesterol biosynthesis, especially postsqualene, in human HepG2 hepatoma cells. We quantified cholesterol and its precursors, and the mRNA and protein levels of enzymes involved in cholesterol biosynthesis. Three L. sakei UONUMA strains exhibited new inhibitory effects on cholesterol biosynthesis and inhibited the mRNA level of sterol-delta24-reductase (DHCR24), which is involved in the postsqualene cholesterol biosynthesis pathway. These strains will be useful for the prevention and treatment of hyperlipidemia.
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.b20-00663